FDA approves JAK inhibitor momelotinib for myelofibrosis with anemiaSeptember 18, 2023CythemiasAnemiaAML
Using JAK inhibitors for myelofibrosisSeptember 11, 2023Myelodysplastic SyndromeAMLAnemiaBleeding DisordersMixed TopicsThrombosisTransfusion Medicine
CHP/CCUS: Low blood cancer risk for most patientsSeptember 8, 2023Mixed TopicsMyelodysplastic SyndromeAnemiaThrombosisPatient & Survivor CareBleeding Disorders
Drugmakers are abandoning cheap generics, and now U.S. cancer patients can’t get medsJune 22, 2023Patient & Survivor CareDLBCLAggressive LymphomasALLAMLAnemiaB Cell Lymphoma
Consider mental health and social factors in management of sickle cell diseaseJune 22, 2023AnemiaPediatrics
Number of cancer survivors with functional limitations doubled in 20 yearsMay 11, 2023Patient & Survivor CareDiversity in MedicineMixed TopicsDLBCLALLAMLAnemia
VEXAS syndrome: More common, variable, and severe than expectedJanuary 24, 2023Myelodysplastic SyndromeAnemia
Study: Formula-fed extreme preemies need more ironDecember 16, 2022Transfusion MedicineAnemiaPediatrics
Post Roe, pregnant SCD patients facing “dire” risksOctober 31, 2022Bleeding DisordersMixed TopicsAnemia
FDA approves first gene therapy, betibeglogene autotemcel (Zynteglo), for beta-thalassemiaAugust 17, 2022Transfusion MedicinePediatricsAnemia
